InvestorsHub Logo
Followers 105
Posts 16383
Boards Moderated 0
Alias Born 06/24/2014

Re: None

Monday, 03/18/2024 8:01:26 AM

Monday, March 18, 2024 8:01:26 AM

Post# of 121
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ZVSA News